Foscarnet
- Atc Codes:J05AD01
- CAS Codes:63585-09-1
- PHARMGKB ID:63585-09-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Foscavir; France: Foscavir; Germany: Foscavir, Triapten; Greece: Foscavir; Hungary: Foscavir; Italy: Foscavir; Luxembourg: Foscavir; Netherlands: Foscavir; Poland: Triapten; Spain: Foscavir; UK: Foscavir.
North America
USA: Foscavir.
Latin America
Argentina: Foscarnet; Brazil: Foscavir.
Asia
Japan: Foscavir.
Drug combinations
Chemistry
Foscarnet Sodium: CNa~3~O~5~P. Mw: 191.95. (1) Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt; (2) Phosphonoformic acid, trisodium salt. CAS-63585-09-1 (1985).
Pharmacologic Category
Miscellaneous Antivirals. (ATC-Code: J05AD01).
Mechanism of action
Foscarnet is an antiviral medicine which works by blocking replication of CMV and other human viruses such as herpes viruses. Similar to ganciclovir, foscarnet is a virostatic agent.
Therapeutic use
Treatment of cytomegalovirus retinitis in acquired immunodeficiency syndrome.
Pregnancy and lactiation implications
There are no adequate, well controlled studies in pregnant women. Lactation not recommended if diagnosed with HIV in order to avoid postnatal transmission of the virus.
Unlabeled use
Other cytomegalovirus infections (e.g. colitis, esophagitis, neurological disease). Cytomegalovirus prophylaxis for cancer patients receiving alemtuzumab therapy or allogeneic stem cell transplant.
Contraindications
Hypersensitivity to foscarnet or any component of the formulation.
Warnings and precautions
Hazardous agent. Dental effects observed in animal studies. Electrolyte/mineral imbalance might occur (use caution in underlying electrolyte imbalances, patients with neurologic or cardiac abnormalities, and those receiving medications influenced by calcium levels). May cause anemia and granulocytopenia. Renal impairment is common and may occur at any time. Use in patients with CrCl <0.4 mL/kg/minute not recommended. Seizures related to plasma electrolyte/mineral imbalance might occur. Vascular irritant.